The post-hoc power analyses for FABP5 and ENO1, based on the sample sizes of BPH (n = 17) and PCa (n = 68) groups, as well as the obtained variance within groups, gave the calculated powers of 0.869 and 0.360, respectively. This evidence concerns the gene ENO1 and benign prostatic hyperplasia.